Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

Diana Rafael; Marcelo Guerrero; Adolfo Marican; Diego Arango; Bruno Sarmento; Roser Ferrer; Esteban F. Durán-Lara; Simon J. Clark; Jr Simo Schwartz

doi:10.3390/pharmaceutics15051484

Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

Diana Rafael, Marcelo Guerrero, Adolfo Marican, Diego Arango, Bruno Sarmento, Roser Ferrer, Esteban F. Durán-Lara, Simon J. Clark, Jr Simo Schwartz

Division of Evolution, Infection and Genomics

Research output: Contribution to journal › Article › peer-review

Abstract

Slow-release delivery systems are needed to ensure long-term sustained treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy, which are currently treated with anti-angiogenic agents that require frequent intraocular injections. These can cause serious co-morbidities for the patients and are far from providing the adequate drug/protein release rates and required pharmacokinetics to sustain prolonged efficacy. This review focuses on the use of hydrogels, particularly on temperature-responsive hydrogels as delivery vehicles for the intravitreal injection of retinal therapies, their advantages and disadvantages for intraocular administration, and the current advances in their use to treat retinal diseases.

Original language	English
Article number	1484
Journal	Pharmaceutics
Volume	15
Issue number	5
DOIs	https://doi.org/10.3390/pharmaceutics15051484
Publication status	Published - 12 May 2023

Keywords

delivery systems
hydrogels
intravitreal delivery
retinopathies
stimuli-responsive
thermo-responsive

Access to Document

10.3390/pharmaceutics15051484

Cite this

@article{d8af5082cf8f4b849f85b224b9bb5b9a,

title = "Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds",

abstract = "Slow-release delivery systems are needed to ensure long-term sustained treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy, which are currently treated with anti-angiogenic agents that require frequent intraocular injections. These can cause serious co-morbidities for the patients and are far from providing the adequate drug/protein release rates and required pharmacokinetics to sustain prolonged efficacy. This review focuses on the use of hydrogels, particularly on temperature-responsive hydrogels as delivery vehicles for the intravitreal injection of retinal therapies, their advantages and disadvantages for intraocular administration, and the current advances in their use to treat retinal diseases.",

keywords = "delivery systems, hydrogels, intravitreal delivery, retinopathies, stimuli-responsive, thermo-responsive",

author = "Diana Rafael and Marcelo Guerrero and Adolfo Marican and Diego Arango and Bruno Sarmento and Roser Ferrer and Dur{\'a}n-Lara, {Esteban F.} and Clark, {Simon J.} and {Simo Schwartz}, Jr",

year = "2023",

month = may,

day = "12",

doi = "10.3390/pharmaceutics15051484",

language = "English",

volume = "15",

journal = "Pharmaceutics",

issn = "1999-4923",

publisher = "MDPI",

number = "5",

}

TY - JOUR

T1 - Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

AU - Rafael, Diana

AU - Guerrero, Marcelo

AU - Marican, Adolfo

AU - Arango, Diego

AU - Sarmento, Bruno

AU - Ferrer, Roser

AU - Durán-Lara, Esteban F.

AU - Clark, Simon J.

AU - Simo Schwartz, Jr

PY - 2023/5/12

Y1 - 2023/5/12

N2 - Slow-release delivery systems are needed to ensure long-term sustained treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy, which are currently treated with anti-angiogenic agents that require frequent intraocular injections. These can cause serious co-morbidities for the patients and are far from providing the adequate drug/protein release rates and required pharmacokinetics to sustain prolonged efficacy. This review focuses on the use of hydrogels, particularly on temperature-responsive hydrogels as delivery vehicles for the intravitreal injection of retinal therapies, their advantages and disadvantages for intraocular administration, and the current advances in their use to treat retinal diseases.

AB - Slow-release delivery systems are needed to ensure long-term sustained treatments for retinal diseases such as age-related macular degeneration and diabetic retinopathy, which are currently treated with anti-angiogenic agents that require frequent intraocular injections. These can cause serious co-morbidities for the patients and are far from providing the adequate drug/protein release rates and required pharmacokinetics to sustain prolonged efficacy. This review focuses on the use of hydrogels, particularly on temperature-responsive hydrogels as delivery vehicles for the intravitreal injection of retinal therapies, their advantages and disadvantages for intraocular administration, and the current advances in their use to treat retinal diseases.

KW - delivery systems

KW - hydrogels

KW - intravitreal delivery

KW - retinopathies

KW - stimuli-responsive

KW - thermo-responsive

UR - http://www.scopus.com/inward/record.url?scp=85160450464&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/e2eda775-6e78-3d07-826c-489f3a707c56/

U2 - 10.3390/pharmaceutics15051484

DO - 10.3390/pharmaceutics15051484

M3 - Article

C2 - 37242726

SN - 1999-4923

VL - 15

JO - Pharmaceutics

JF - Pharmaceutics

IS - 5

M1 - 1484

ER -

Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this